Spectranetics (Nasdaq: SPNC ) is expected to report Q2 earnings on July 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Spectranetics's revenues will grow 10.4% and EPS will shrink to a loss.
The average estimate for revenue is $38.7 million. On the bottom line, the average EPS estimate is -$0.02.
Last quarter, Spectranetics reported revenue of $37.7 million. GAAP reported sales were 12% higher than the prior-year quarter's $33.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.01. GAAP EPS were -$0.03 for Q1 versus $0.00 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 72.2%, 80 basis points worse than the prior-year quarter. Operating margin was -3.5%, 330 basis points worse than the prior-year quarter. Net margin was -2.6%, 260 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $155.4 million. The average EPS estimate is $0.01.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 153 members out of 170 rating the stock outperform, and 17 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Spectranetics a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Spectranetics is outperform, with an average price target of $19.90.
Is Spectranetics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Spectranetics to My Watchlist.